Understanding why patients with blood cancers start and stick with oral cancer medicines
Official title: Identifying Multi-Level Predictors and Outcomes of Oral Anticancer Medication Adherence Initiation and Persistence among Patients with Hematologic Malignancies
Funded at Ohio State University · NIH-11611692 · Data updated 2026-11-12
A study to learn what helps or hinders Black patients with blood cancers in starting and continuing their prescribed oral cancer medicines.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $547,154 |
| NIH project number | 7R01CA292925-03 |
| Project ID | NIH-11611692 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with hematologic malignancies (MM, CML, CLL) who are prescribed long-term oral anticancer medications, especially Black/African American patients.
✕Less likely to help
Patients not starting or continuing OAM therapy or those without access to healthcare support may not experience benefit.
What this research studies
Patients with multiple myeloma, CML, and CLL rely on long-term oral anticancer medications, but many struggle to start or stay on therapy. The study will look at personal, clinical, and system factors that influence initiation and persistence, using patient data and real-world experiences. By identifying where barriers occur, researchers hope to suggest ways to improve access, affordability, and support for adherence.
Why it matters
Potential benefit: If successful, findings could lead to targeted strategies to improve adherence and outcomes for patients taking oral anticancer medicines.
How similar studies have gone: Previous work showed adherence patterns vary and are linked to quality of life, but more work is needed in hematologic cancers and diverse populations.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Belcher, Sarah M. — Ohio State University
- Study coordinator: Belcher, Sarah M.
Related research
Other NIH-funded projects on the same topics.
-
What helps people with blood cancers start and keep taking oral cancer medicines
This project looks at why people with blood cancers (like CLL, CML, and multiple myeloma) do or don't start and stick with prescribed oral cancer medicines.
-
Understanding why patients with blood cancers may not take their oral cancer medications as prescribed
This study is looking at what helps or hinders patients with blood cancers, like multiple myeloma and chronic lymphocytic leukemia, from starting and sticking to their oral cancer medications, so we can find better ways to support them and improve their health and quality of life.
-
Adapting flow cytometry to detect childhood leukemias in Kenya using a single-test screen
A low-cost, blood-based flow cytometry screen in Kenya aims to detect and triage suspected leukemias in children and young adults.
-
Incentives and Anchoring to Improve Long-term HIV Medication Adherence
A study tests a simple, daily habit plan combined with friendly reminders and small rewards to help people living with HIV take their ART pills on time.
-
WeCare: a combined mental health and HIV medication support program for high-risk men
A patient-friendly program called WeCare aims to support mental health and improve adherence to HIV meds among high-risk men in settings with limited resources.
-
Why some blood cancer cells survive after treatment by resisting natural killer cells
This work is trying to understand why leftover blood cancer cells in leukemia and multiple myeloma survive treatment by escaping natural killer immune cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.